ProCE Banner Activity

ART 期间的不良事件和治疗意义:2021 年夏季关键数据

Text Module

回顾专家讨论,了解来自 IAS 2021 的新数据如何扩大我们对特定 ART 方案的不良事件概况的理解,特别关注体重、BMI、胰岛素抵抗和其他代谢参数。

Released: October 29, 2021



Eric S. Daar

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner



ViiV Healthcare

Learning Objectives

Upon completion of this activity, participants should be able to:

  • 针对接受病毒学抑制治疗方案时发生不良事件或耐受性差的患者制定恰当的 ART 修改策略
  • 制定旨在避免禁忌症和尽量减少不良事件的策略以优化针对特殊人群的 HIV 医疗护理工作


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Eric S. Daar 博士和 Clinical Care Options (CCO) 观点,专家讨论了来自 IAS 2021 的新数据如何扩大我们对特定 ART 方案的不良事件的理解

Staff Disclosure


Quentin Minson, PharmD

Director of Educational Strategy

Quentin Minson(药学博士、BCPS、BCIDP)没有要报告的相关利益冲突。

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran D. Mir-Hudgeons(哲学博士)没有要报告的相关利益冲突。

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz(理学硕士、ELS)没有要报告的相关利益冲突。

Julie Skowronski, FNP-BC

Julie Skowronski (FNP-BC) 没有要报告的相关利益冲突。

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.